Flatiron's Ingredient Drug Substitution for 505(b)(2) with Tennessee Oncology

The rapid growth of 505(b)(2) drugs -- generic-like alternatives that differ from originator drugs in formulation and administration -- creates formulary-management and payer-compliance burdens for oncology practices. Flatiron built an automated ingredient drug-substitution feature in OncoEMR letting practices create customizable substitution groups matching their preferences and payer requirements. Tennessee Oncology, a 71-physician community cancer center, adopted the feature and achieved a 16-point increase in order accuracy, with 80% of flowsheets with substitutions accurate at point of ordering and an 80% decrease in manual substitutions and post-ordering changes, saving roughly 4-8 hours per week on manual tasks.

Flatiron Health is a Roche-owned company supplying EHR-derived oncology real-world data, captured at the source through its own OncoEMR software.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.